| Literature DB >> 35456563 |
Solen Novello1,2,3, Sylvie Tricot-Doleux1, Agnès Novella1, Pascal Pellen-Mussi1, Sylvie Jeanne1,2,3.
Abstract
Mesenchymal stem cells (MSC) are involved in the regeneration of various missing or compromised periodontal tissues, including bone. MSC-derived conditioned medium (CM) has recently been explored as a favorable surrogate for stem cell therapy, as it is capable of producing comparable therapeutic effects. This study aimed to evaluate the influence of periodontal ligament stem cells (PDLSC)-CM on osteoblasts (OB) and its potential as a therapeutic tool for periodontal regeneration. Human PDLSC were isolated and characterized, and CM from these cells was collected. The presence of exosomes in the culture supernatant was observed by immunofluorescence and by transmission electron microscopy. CM was added to a cultured osteoblastic cell line (Saos-2 cells) and viability (MTT assay) and gene expression analysis (real-time PCR) were examined. A cell line derived from the periodontal ligament and showing all the characteristics of MSC was successfully isolated and characterized. The addition of PDLSC-CM to Saos-2 cells led to an enhancement of their proliferation and an increased expression of some osteoblastic differentiation markers, but this differentiation was not complete. Saos-2 cells were involved in the initial inflammation process by releasing IL-6 and activating COX2. The effects of PDLSC-CM on Saos-2 appear to arise from a cumulative effect of different effective components rather than a few factors present at high levels.Entities:
Keywords: bone regeneration; conditioned medium; exosomes; mesenchymal stem cells; osteoblasts; periodontal regeneration
Year: 2022 PMID: 35456563 PMCID: PMC9028528 DOI: 10.3390/pharmaceutics14040729
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Description and characteristics of primers used for RT-qPCR. Abbreviations: ALP, alkaline phosphatase; COL1, collagen 1; OCN, osteocalcin; OP, osteopontin; RunX2, Runt-related transcription factor 2; COX2, cyclooxygenase-2; VEGF, vascular endothelial growth factor; HSP, heat shock protein; IL, interleukin, BSP, bone sialoprotein.
| Amorce | Sequence 5′-3′ | Exon | Product Size (bp) | Primer | Coefficient of |
|---|---|---|---|---|---|
|
| F: ATTAAGGGTGTGGGCCGAAG | F: E1/2 | 111 | 96.1 | 1 |
|
| F: AGCTTGCTGGTGAAAAGG | F: E6/7 | 107 | 97.6 | 0.99 |
|
| F: AGAACCCCAAAGGCTTCTTC | F: E7 | 74 | 99.2 | 1 |
|
| F: CGAAGACATCCCACCAATCAC | F: E1/2 | 98 | 99.7 | 0.999 |
|
| F: GCAGCGAGGTAGTGAAGAGA | F: E3 | 137 | 93.9 | 0.99 |
|
| F: TCACCTGTGCCATACCAGTTAAA | F: E2/3 | 85 | 101.8 | 0.99 |
|
| F: ACCCAGAAGGCACAGACAGAAG | F: E5/6 | 82 | 99.7 | 1 |
|
| F: TGCGCCTTTTCAAGGATGGA | F: E6 | 134 | 91.7 | 0.98 |
|
| F: TTGCCTTGCTGCTCTACCTCCA | F: E1 | 126 | 96.9 | 1 |
|
| F: TGGATGTCAACCACTTCGCC | F: E1 | 106 | 106.6 | 0.93 |
|
| F: GACGACCTGTCTCGCCG | F: E1 | 78 | 106.5 | 1 |
|
| F: TTGTGCAGTTGCCTACAGGA | F: E3 | 85 | 103.6 | 1 |
|
| F: GATCACTTGGCAGTGAAGCATT | F: E6/7 | 79 | 90.8 | 1 |
|
| F: CCAGAGCTGTGCAGATGAGTA | F: E4 | 89 | 95.2 | 1 |
|
| F: ACCACCGGAAGGAACCATCT | F: E1 | 121 | 93.5 | 0.99 |
|
| F: AACGAAGAAAGCGAAGCAGAA | F: E7 | 77 | 96.2 | 0.99 |
hPDLSC surface antigen expression (%) analyzed by flow cytometry.
| CD34 | CD45 | CD73 | CD90 | CD105 | |
|---|---|---|---|---|---|
| hPDLSC | 0.36 | 0.34 | 99.97 | 99.97 | 96.77 |
| Control | 0.17 | 0.05 | 0.26 | 0.08 | 0.45 |
Figure 1Characterization of hPDLSC. (A) Colony-forming assay. (B) Alizarin red staining (Scale bar = 100 µm). (C) Oil Red O staining (Scale bar = 50 µm).
Figure 2Immunofluorescence staining of hPDLSC with CD9 (A), CD63 (B), and ALIX (C). Negative control with non-immune serum (D). Objective 40×/1.0 PL Fluotar. Scale bars = 25 µm.
Figure 3TEM observation: exosomes (A) and example of immunogold labeled exosomes with anti-CD63 (B). Scale bars = 200 nm (A) and 100 nm (B).
Figure 4Expression of IL-6 and IL-8 in hPDLSC-CM, compared with supernatant and cell-free medium.
Figure 5Cell viability of Saos-2 analyzed by MTT assay after 48 or 72 h of treatment with different concentrations of CM (* p < 0.05).
Figure 6Quantitative reverse transcription-polymerase chain reaction demonstrating the effect of hPDLSC-CM on Saos-2 gene expression. RGE: Relative Gene Expression. * p < 0.05; ** p < 0.01; *** p < 0.001.